Stocks · Healthcare · Drug Manufacturers - Specialty & Generic
Emergent BioSolutions Inc. EBS
$6.33 -0.63% Close, Oct 2, 2026 · NYSE · Market cap $326.6M
Weak trendHigh risk
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $-3.55, down 245.3% year over year.
- Operating margin narrowed to -7.1% from 12.2% a year earlier.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 19%
- EPS growth (TTM, YoY)Bottom 9%
- FCF growth (TTM, YoY)Bottom 18%
- Revenue growth, 3-year CAGRBottom 10%
- Revenue growth accelerationTop 8%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 39%
- Gross marginBottom 33%
- Operating marginTop 50%
- Accruals (lower is better)Top 9%
- Interest coverTop 47%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 13%
- Free-cash-flow yieldTop 2%
- EBITDA / enterprise valueTop 46%
- Sales / enterprise valueTop 10%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 17%
- 6-month returnBottom 22%
- 1-year return vs S&P 500Bottom 21%
- Distance from 52-week highBottom 23%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyBottom 44%
- Upside to consensus price targetBottom 49%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 12%
- Maximum drawdown, 3 yearsBottom 48%
- Beta vs S&P 500 (lower is better)Bottom 11%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -29.9% | -9.6% | ↑ |
| Gross margin | 55.7% | 49.4% | ↓ |
| Operating margin | 12.2% | -7.1% | ↓ |
| FCF margin | 18.2% | 11.2% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -9.6% | -29.9% | ↑ | Bottom 19% |
| EPS growth (TTM, YoY) | -245.3% | — | Bottom 9% | |
| Gross margin | 49.4% | 55.7% | ↓ | Bottom 33% |
| Operating margin | -7.1% | 12.2% | ↓ | Top 50% |
| Net margin | -23.0% | 16.4% | ↓ | — |
| Free-cash-flow margin | 11.2% | 18.2% | ↓ | — |
| Return on invested capital | -5.5% | — | Top 39% | |
| Revenue growth, 3-year CAGR | -12.7% | — | Bottom 10% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -24.6%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 2.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +147.7 pp
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -1.1×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 10.17%
- Shareholder yield
- 10.17%
- Share count change, 1 year
- -4.8%
- Share count change, 3-year CAGR
- +0.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 7 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- -0.7%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $10.00
- Target vs current price
- +58.0%
- Analysts with a rating
- 15
- Share rating Buy or Strong Buy
- 73%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +805.9% | -0.4% | -41.2% | -17.8% | — |
| Apr 30, 2026 | +184.0% | +3.0% | +13.9% | +14.9% | -8.3% |
| Feb 26, 2026 | -490.9% | +0.8% | -20.3% | -25.4% | -24.0% |
| Oct 29, 2025 | +983.3% | -0.7% | +6.5% | +15.6% | +25.8% |
| Aug 6, 2025 | +161.5% | -1.1% | +46.1% | +28.4% | +54.1% |
| May 7, 2025 | +44.9% | -1.0% | +22.8% | +32.2% | +17.5% |
| Mar 3, 2025 | +114.3% | -8.7% | -22.9% | -37.7% | -15.5% |
| Nov 6, 2024 | +179.6% | +2.7% | +21.5% | +5.2% | +19.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | $0.60 | -$0.09 | +805.9% | $234.3M |
| Apr 30, 2026 | $0.21 | -$0.25 | +184.0% | $156.1M |
| Feb 26, 2026 | -$0.43 | $0.11 | -490.9% | $148.7M |
| Oct 29, 2025 | $1.06 | -$0.12 | +983.3% | $231.1M |
| Aug 6, 2025 | $0.16 | -$0.26 | +161.5% | $140.9M |
| May 7, 2025 | $0.71 | $0.49 | +44.9% | $222.2M |
| Mar 3, 2025 | $0.05 | -$0.35 | +114.3% | $189.3M |
| Nov 6, 2024 | $1.37 | $0.49 | +179.6% | $293.8M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (forward) | 17.6× | — | — | — |
| EV / Sales | 1.00× | — | — | Top 10% |
| Free-cash-flow yield | 26.30% | — | — | Top 2% |
| Earnings yield | -56.01% | — | — | Bottom 13% |
P/E over the past five years
Range 3.4× – 17.9× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- -31.1%
- Earnings per share growth (TTM)
- -245.3%
- Change in P/E multiple
- -45.9%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 13
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -8.9%
- 200-day average slope (20 days)
- -5.0%
- Distance from 50-day average
- +3.3%
- Distance from 200-day average
- -26.4%
- RSI (14)
- 47.7
- Relative volume
- 0.55×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 90.7%
- Volatility vs own 5-year history
- 58th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.10
- Correlation with S&P 500
- 0.36
- Current drawdown from 1-year high
- -54.5%
- Maximum drawdown, 3 years
- -71.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 12, 2021 | Feb 7, 2024 | -98.8% | 750 days | Not yet recovered |
| Oct 12, 2020 | Nov 24, 2020 | -29.0% | 31 days | 45 days (Feb 1, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $326.6M
- EPS, diluted (TTM)
- -$3.55
- Revenue (TTM)
- $770.2M
- 52-week range
- $4.36 – $14.06
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $1.77B | $1.12B | $1.05B | $1.04B | $742.9M |
| Gross profit | $793.2M | $473.0M | $360.0M | $375.4M | $350.6M |
| Operating income | $341.4M | -$170.0M | -$726.4M | -$108.7M | $110.2M |
| Net income | $219.5M | -$211.6M | -$760.5M | -$190.6M | $52.6M |
| EPS (diluted) | $4.06 | -$4.22 | -$14.85 | -$3.60 | $0.93 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $293.8M | $194.7M | $222.2M | $140.9M | $231.1M | $148.7M | $156.1M | $234.3M |
| Net income | $114.8M | -$31.3M | $68.0M | -$12.0M | $51.2M | -$54.6M | $6.8M | -$180.2M |
| EPS (diluted) | $2.06 | -$0.59 | $1.19 | -$0.22 | $0.91 | -$1.04 | $0.07 | -$3.49 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $321.1M | -$34.1M | -$206.3M | $58.7M | $170.6M |
| Capital expenditure | -$225.0M | -$115.8M | -$51.6M | -$22.9M | -$13.8M |
| Free cash flow | $96.1M | -$149.9M | -$257.9M | $35.8M | $156.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | -$106.0M | -$82.1M | $8.4M | $9.3M | -$22.7M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $139.7M
- Total assets
- $1.12B
- Total liabilities
- $775.4M
- Total debt
- $581.8M
- Net debt
- $442.1M
- Shareholders’ equity
- $341.4M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 9,786,380
- Days to cover
- 8.60
- Change vs previous report
- -9.7%
FINRA short interest, settlement date Sep 15, 2026.